期刊
NETHERLANDS HEART JOURNAL
卷 22, 期 10, 页码 463-469出版社
BOHN STAFLEU VAN LOGHUM BV
DOI: 10.1007/s12471-014-0590-4
关键词
Cardiac troponin I; Phosphorylation; Myofilament function; Heart failure
资金
- National Institute of Health (NIH) [R01 HL063038, NIH R01 HL76038]
- Netherlands Organisation for Scientific Research (NWO
- VIDI grant)
- European Society of Cardiology Research Grant
Cardiac troponin I (cTnI) is well known as a biomarker for the diagnosis of myocardial damage. However, because of its central role in the regulation of contraction and relaxation in heart muscle, cTnI may also be a potential target for the treatment of heart failure. Studies in rodent models of cardiac disease and human heart samples showed altered phosphorylation at various sites on cTnI (i.e. site-specific phosphorylation). This is caused by altered expression and/or activity of kinases and phosphatases during heart failure development. It is not known whether these (transient) alterations in cTnI phosphorylation are beneficial or detrimental. Knowledge of the effects of site-specific cTnI phosphorylation on cardiomyocyte contractility is therefore of utmost importance for the development of new therapeutic strategies in patients with heart failure. In this review we focus on the role of cTnI phosphorylation in the healthy heart upon activation of the beta-adrenergic receptor pathway (as occurs during increased stress and exercise) and as a modulator of the Frank-Starling mechanism. Moreover, we provide an overview of recent studies which aimed to reveal the functional consequences of changes in cTnI phosphorylation in cardiac disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据